Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to prove the hypothesis that the progression of renal and cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker valsartan is added to conventional antihypertensive therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: KVT-Study Group
• Collaborators: Kitasato University; Showa University; St. Marianna University School of Medicine; Tokai University; Yokohama City University
• Treatments: Antihypertensive Agents; Valsartan

Criteria

Inclusion Criteria:

• CKD with serum creatinine more than 2.0 mg/dl

• Blood pressure more than 130/85 mmHg

• 20 years old or above

Exclusion Criteria:

• End-stage renal disease with maintenance dialysis

• Polycystic kidney disease

• Collagen disease

• Malignant or accelerated hypertension